-
- Masayuki Amagai
- Department of Dermatology Keio University School of Medicine Tokyo Japan
-
- Akiko Tanikawa
- Department of Dermatology Keio University School of Medicine Tokyo Japan
-
- Tomoko Shimizu
- Department of Dermatology Keio University School of Medicine Tokyo Japan
-
- Takashi Hashimoto
- Department of Dermatology Kurume University School of Medicine Kurume Japan
-
- Shigaku Ikeda
- Department of Dermatology Juntendo University Faculty of Medicine Tokyo Japan
-
- Michiko Kurosawa
- Department of Epidemiology and Environmental Health Juntendo University Faculty of Medicine Tokyo Japan
-
- Hironori Niizeki
- Department of Dermatology National Center for Child Health and Development Tokyo Japan
-
- Yumi Aoyama
- Department of Dermatology Okayama University Graduate School of Medicine Okayama Japan
-
- Keiji Iwatsuki
- Department of Dermatology Okayama University Graduate School of Medicine Okayama Japan
-
- Yasuo Kitajima
- Kizawa Memorial Hospital Gifu Japan
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee for Intractable Skin Disease. Pemphigus has been defined as a group of intractable autoimmune blistering diseases caused by anti‐desmoglein 1 and/or anti‐desmoglein 3 IgG autoantibodies by the MHLW. The diagnosis of this condition and the criteria for assessing its severity are based on suggestions from the MHLW Research Group. The clinical practice guidelines presented here are those that are currently recommended in Japan. However, symptoms and complications can vary widely among individual pemphigus patients, so not all therapies will be required to be in complete agreement with these guidelines.</jats:p>
収録刊行物
-
- The Journal of Dermatology
-
The Journal of Dermatology 41 (6), 471-486, 2014-06
Wiley
